Balyasny Asset Management L.P. and related reporting persons filed an amended beneficial ownership statement with the SEC on November 16, 2026, disclosing a 7.94% stake in SAB Biotherapeutics, Inc. (NASDAQ:SABS) as of September 30, 2026.

Key Highlights

  • Aggregate beneficial ownership: Each of the five reporting persons is listed as beneficially owning 7,225,439 shares of SAB Biotherapeutics common stock.
  • Percent of class: The 7,225,439 shares represent approximately 7.94% of the issuer's outstanding shares, based on 90,986,368 shares outstanding as of August 3, 2026.
  • Composition of reported shares: The filing states the reported amount consists of 3,760,439 shares and 3,465,000 shares issuable upon exercise of 34,650 warrants, subject to a Beneficial Ownership Limitation.
  • Beneficial Ownership Limitation: The warrants include a blocker preventing exercise if the resulting ownership would exceed 9.99% of outstanding shares.
  • Sole voting and dispositive power: Each reporting person is listed as holding sole voting power and sole dispositive power over all 7,225,439 shares, with zero shared voting or dispositive power.
  • Triggering event date: The date of the event requiring this filing is stated as September 30, 2026.
  • Five reporting persons: The filers are Balyasny Asset Management L.P., BAM GP LLC, Balyasny Asset Management Holdings LP, Dames GP LLC, and Dmitry Balyasny.

Balyasny's Amended Position in SAB Biotherapeutics Common Stock

According to the filing, Balyasny Asset Management L.P. ("BAM"), a Delaware limited partnership, acts as investment manager for two direct holders: Atlas Diversified Master Fund, Ltd ("ADMF"), which directly holds 1,450,439 shares, and Atlas Private Holdings (Cayman) Ltd. ("APHC"), which directly holds 2,310,000 shares along with an additional 3,465,000 shares issued upon the exercise of warrants. By virtue of these investment management roles, BAM and each of the other four reporting persons may be deemed to beneficially own all 7,225,439 shares in aggregate, the filing disclosed.

The corporate chain described in the filing runs from BAM upward through BAM GP LLC as BAM's general partner, then to Balyasny Asset Management Holdings LP as BAM GP's sole member, then to Dames GP LLC as the general partner of BAM Holdings, and finally to Dmitry Balyasny as the managing member of Dames. SAB Biotherapeutics, the issuer, is a biopharmaceutical company whose principal executive offices are listed at 777 W 41st St, Suite 401, Miami Beach, Florida, 33140, according to the filing.

This is Amendment No. 2 to the original filing. The percent of class figure of 7.94% is calculated against the 90,986,368 shares outstanding as of August 3, 2026, as reported in the issuer's Form 10-Q filed with the SEC on August 6, 2026, the filing stated. The warrant blocker caps any exercise that would cause the holder's beneficial ownership to exceed 9.99% of shares outstanding at the time of exercise.

What Was Disclosed

Balyasny Asset Management L.P. and four affiliated entities and individuals filed an amended beneficial ownership statement covering 7,225,439 shares, or approximately 7.94%, of SAB Biotherapeutics common stock (CUSIP 78397T202) as of September 30, 2026, including shares issuable upon warrant exercise subject to a 9.99% ownership cap.